Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

7.6%

5 terminated/withdrawn out of 66 trials

Success Rate

83.9%

-2.6% vs industry average

Late-Stage Pipeline

23%

15 trials in Phase 3/4

Results Transparency

15%

4 of 26 completed trials have results

Key Signals

7 recruiting4 with results

Enrollment Performance

Analytics

N/A

34(60.7%)

Phase 4

9(16.1%)

Phase 3

6(10.7%)

Phase 2

5(8.9%)

Early Phase 1

1(1.8%)

Phase 1

1(1.8%)

56Total

N/A(34)

Phase 4(9)

Phase 3(6)

Phase 2(5)

+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (66)

Showing 20 of 66 trials

NCT07463092Not ApplicableRecruiting

Creatine Supplementation and Resistance Training to Improve Sarcopenia Parameters in Patients With Prostate Cancer After Androgen Deprivation Therapy

Role: collaborator

NCT07314268Recruiting

ATTR Amyloid Cardiomyopathy: Characterization of Extracellular Vesicles as Potential Disease Stratifiers and Prognostic Biomarkers

Role: collaborator

NCT07303842Not ApplicableCompleted

Effect of a Low Advanced Glycation End Products Diet of Patients With Type 2 Diabetes Mellitus

Role: lead

NCT05877235Not ApplicableCompleted

Serum Concentration of Endogenous Estrogens and Sirtuin-1 After Administration of Atorvastatin and Quercetin:

Role: lead

NCT06611527Not ApplicableRecruiting

Positive Pressure Therapy to Optimize LUNG Function After Heart Surgery

Role: collaborator

NCT05519046Not ApplicableRecruiting

Cardiac Contractility Modulation in Chagas Heart Disease

Role: lead

NCT06720662Not ApplicableNot Yet Recruiting

Effect of Icosapent-ethyl Ester (IPE) to Reduce the Residual Risk Cardiovascular Disease.

Role: collaborator

NCT04853758Phase 3Recruiting

Angiotensin Receptor-Neprilysin Inhibition in Chagas Cardiomyopathy With Reduced Ejection Fraction: ANSWER-HF.

Role: collaborator

NCT05611268Not ApplicableRecruiting

Pentoxifylline as an Adjunct Therapy for Patients With Eisenmenger Syndrome

Role: collaborator

NCT02170103Not ApplicableCompleted

Microvascular Recovery With Ultrasound in Myocardial Infarction (MRUSMI) Post PCI Trial

Role: collaborator

NCT00955136Not ApplicableWithdrawn

Utilization of Diagnostic Ultrasound in the Detection and Therapy of Acute Coronary Syndromes

Role: collaborator

NCT02514226Not ApplicableUnknown

Evaluation of Periodontal Treatment in Patients With Bronchiectasis

Role: collaborator

NCT04163653Completed

Lymphatic Morphology of Fontan Patients

Role: collaborator

NCT05384379Early Phase 1Terminated

Efficacy and Safety Evaluation of BZ371B in ARDS Patients

Role: collaborator

NCT04361006Not ApplicableCompleted

Cryotherapy Versus Radiofrequency Ablation for Treatment of Para-hisian Accessory Pathways

Role: collaborator

NCT05843682Not ApplicableUnknown

Technological Innovation in the Virtual Assistance of Patients With Uncontrolled Arterial Hypertension - Hyper 2

Role: collaborator

NCT05808387Not ApplicableRecruiting

The Effects of Resveratrol on Sirtuins and Apoptosis Biomarkers

Role: lead

NCT02574156Phase 3Terminated

Control of Hyperglycemia After Cardiac Surgery: CHyCS Trial

Role: collaborator

NCT02208830Not ApplicableCompleted

Physical Capacity in Patients With Bronchiectasis Before and After Rehabilitation Program

Role: collaborator

NCT02325505Completed

Characterization of Patients With Tuberous Sclerosis Complex, Lymphangioleiomyomatosis and Angiomyolipoma

Role: lead